Financial PerformanceManagement noted that orders grew 13% YoY in 3Q24 and revenue per sales rep increased 25% YoY to approximately $530,000.
Market EntryIf cleared by the FDA, NiCO would allow Zynex to enter the multi-billion dollar pulse oximetry market with differentiating precision and accuracy.
Product PortfolioThe company now has a broadened product portfolio for pain management, which should help drive order growth in the coming quarters.